Amyris - von 500 auf 2,50 Dollar und jetzt wieder zurück? (Seite 35)
eröffnet am 22.08.17 12:11:52 von
neuester Beitrag 12.09.23 08:49:18 von
neuester Beitrag 12.09.23 08:49:18 von
Beiträge: 472
ID: 1.259.956
ID: 1.259.956
Aufrufe heute: 0
Gesamt: 48.016
Gesamt: 48.016
Aktive User: 0
ISIN: US03236M2008 · WKN: A2DS41 · Symbol: AMRSQ
0,0020
USD
0,00 %
0,0000 USD
Letzter Kurs 08.05.24 Nasdaq OTC
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
9,4490 | +125,06 | |
17,495 | +45,07 | |
1,3300 | +30,51 | |
1,9700 | +27,10 | |
1,9800 | +26,11 |
Wertpapier | Kurs | Perf. % |
---|---|---|
0,7200 | -18,18 | |
5,7500 | -18,44 | |
1,7490 | -19,62 | |
2,8800 | -28,71 | |
3,5200 | -74,14 |
Beitrag zu dieser Diskussion schreiben
So könnte jetzt endlich mal gut werden 😉
Hat hier noch jemand Durchgehalten?
Amyris Announces Execution of Definitive Agreements for up to an Anticipated $70 Million Debt Reduction Via Exercise of Existing Warrants and $42 Million in New Financing https://seekingalpha.com/pr/17766731?source=ansh $AMRS
Hat hier noch jemand Durchgehalten?
Amyris Announces Execution of Definitive Agreements for up to an Anticipated $70 Million Debt Reduction Via Exercise of Existing Warrants and $42 Million in New Financing https://seekingalpha.com/pr/17766731?source=ansh $AMRS
Amyris Continues to Deliver Strong Revenue Growth https://seekingalpha.com/pr/17692113?source=ansh $AMRS
Amyris, Inc. 2019 Q3 - Results - Earnings Call Presentation https://seekingalpha.com/article/4304133?source=ansh $AMRS
Amyris' (AMRS) CEO John Melo on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4304131?source=ansh $AMRS
Amyris, Inc. 2019 Q3 - Results - Earnings Call Presentation https://seekingalpha.com/article/4304133?source=ansh $AMRS
Amyris' (AMRS) CEO John Melo on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4304131?source=ansh $AMRS
Amyris, Inc.: A Sweet Future Brought To You By John Doerr https://seekingalpha.com/article/4298152?source=ansh $AMRS
https://seekingalpha.com/article/4295691-amyris-life-support…
Was der Doerr mit der filletierten Amyris anfangen will erschließt sich mir auch nicht....in der Firma ist kaum noch etwas was eine derart hohe Kapitalisierung rechtfertigt...
Was der Doerr mit der filletierten Amyris anfangen will erschließt sich mir auch nicht....in der Firma ist kaum noch etwas was eine derart hohe Kapitalisierung rechtfertigt...
On September 16, 2019, the Company failed to pay an aggregate of $63.6 million of outstanding principal and accrued interest on the Second Exchange Note when due. The failure resulted in an event of default under the Second Exchange Note and also triggered cross-defaults under other debt instruments of the Company which permitted the holders of such indebtedness to accelerate the amounts owing under such instruments. The Company subsequently received waivers from substantially all holders of such other debt instruments to waive the right to accelerate. As a result, the indebtedness with respect to which the Company has obtained such waivers continues to be classified as long-term on the Company’s balance sheet. The indebtedness reflected by the Second Exchange Note continues to be classified as a current liability on the Company’s balance sheet. In addition, as a result of the payment default, the conversion price of the Second Exchange Note is subject to adjustment in accordance with the terms of the Second Exchange Note.
The Company does not currently have sufficient funds to repay the amounts outstanding under the Second Exchange Note. To date, negotiations with the holder of the Second Exchange Note have not been successful, and there can be no assurance that a favorable outcome for the Company will be reached. The Company has executed a term sheet with an existing investor for a term loan, the proceeds of which would be used to repay a portion of the Second Exchange Note. However, there can be no assurance that the Company will be able to obtain such financing on its expected timeline, or on acceptable terms, if at all. Even if the Company does obtain such financing, it will not have sufficient funds to repay the Second Exchange Note in full without obtaining additional financing, which the Company is attempting to source. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
https://www.sec.gov/Archives/edgar/data/1365916/000117184319… (Seite 11)
Upsi - kleine Kettenreaktion - mal sehen was sie jetzt aus dem Zylinder zaubern
The Company does not currently have sufficient funds to repay the amounts outstanding under the Second Exchange Note. To date, negotiations with the holder of the Second Exchange Note have not been successful, and there can be no assurance that a favorable outcome for the Company will be reached. The Company has executed a term sheet with an existing investor for a term loan, the proceeds of which would be used to repay a portion of the Second Exchange Note. However, there can be no assurance that the Company will be able to obtain such financing on its expected timeline, or on acceptable terms, if at all. Even if the Company does obtain such financing, it will not have sufficient funds to repay the Second Exchange Note in full without obtaining additional financing, which the Company is attempting to source. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
https://www.sec.gov/Archives/edgar/data/1365916/000117184319… (Seite 11)
Upsi - kleine Kettenreaktion - mal sehen was sie jetzt aus dem Zylinder zaubern
http://wsw.com/webcast/hcw5/amrs/index.aspx
Also Laut Ceo schafft es Amyris bis Ende September tatsächlich die 10k und 10q zu liefern.
Operativ scheint alles gut zu laufen. Ich hoffe dass es dieses Mal mehr als nur versprechen sind.
Ich bin allerdings recht optimistisch.
Also Laut Ceo schafft es Amyris bis Ende September tatsächlich die 10k und 10q zu liefern.
Operativ scheint alles gut zu laufen. Ich hoffe dass es dieses Mal mehr als nur versprechen sind.
Ich bin allerdings recht optimistisch.
Man muss hier schon echt Nerven haben...🤪
Pricing Amyris Into 2020 https://seekingalpha.com/article/4283452?source=ansh $AMRS, $ACB, $BYND, $GWPH, $JNJ, $TWST
Pricing Amyris Into 2020 https://seekingalpha.com/article/4283452?source=ansh $AMRS, $ACB, $BYND, $GWPH, $JNJ, $TWST
Bestimmt demnächst dann wieder durch irgendwas -30% oder so. Was für ne Aktie. 😂
Amyris - von 500 auf 2,50 Dollar und jetzt wieder zurück?